Lab Manager | Run Your Lab Like a Business

Olympus and Cytosurge Collaborate to Deliver a Complete Single-Cell and CRISPR Genetic Manipulation Solution in the Americas

The FluidFM® BOT BIO Series combines Olympus’ renowned optics with Cytosurge’s cell manipulation expertise

by Olympus Corporation
Register for free to listen to this article
Listen with Speechify

WALTHAM, MA — July 23, 2020 — Olympus, a leading manufacturer of high-end research microscopes, and Cytosurge, a precision manufacturer of cell manipulation technologies, have entered a co-marketing agreement to become a complete system provider to the scientific community’s growing need for next-generation single-cell and CRISPR genetic manipulation solutions.

The demand continues to rise as researchers see their potential to study diseases, find medical treatments, and benefit human health. Cytosurge provides a powerful genetic manipulation solution with the FluidFM® BOT BIO Series, a highly automated system built on the Olympus IX83 inverted microscope with Olympus’ renowned optics. In addition to CRISPR genome editing, the system’s core functionalities—intracellular- and nuclear- injection and extraction, pick-and-place at the microscale, and precise dispensing of liquids—enable a broad range of applications, including single-cell drug assays, monoclonal cell line development, and nanoprinting of custom patterns.

Get training in Lab Crisis Preparation and earn CEUs.One of over 25 IACET-accredited courses in the Academy.
Lab Crisis Preparation Course

“We are very excited to formalize a partnership with Cytosurge, as we have worked with them for many years,” said Lee Wagstaff, vice president of life science sales and marketing at Olympus Corporation of the Americas. “With the FluidFM BOT BIO Series, we see tremendous potential for continued collaboration to blend our optical technologies with their high-precision cell manipulation technologies.” 

Wagstaff continued, “The increasing interest in CRISPR genetic manipulation is just one of the many important trends that shows the importance of using this technology to help understand the biological mechanisms of disease and improve the health and well-being of society. We look forward to increasing our joint activities, which will aid researchers in academia, the pharmaceutical industry and precision medicine field.”

Cytosurge CEO Pascal Behr commented, “The USA was the last missing key market in Cytosurge’s strategic development plan to cover the globe. Our new partnership with Olympus Corporation of the Americas epitomizes the objectives and values of our company, embodying a very high level of understanding and mutual trust. Everything is ready for a rapid and effective market launch to make our remarkable FluidFM technology available on the American continent. With this, we are empowering researchers in both academia and the private sector to go beyond current technological barriers and help them bring new, much-needed therapies and medications to the market faster.”

For more information about Olympus microscopes, visit

For more information about the Cytosurge FluidFM BOT BIO Series, visit

Evident Scientific Logo

Evident Scientific

48 Woerd Avenue
Waltham, Massachusetts
USA 02453